EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Mitochondrial transfer in acute myeloid leukaemia and multiple myeloma: Mechanisms, consequences and potential therapeutic opportunities

Ebubechukwu Nwarunma iD, Mark T S Williams iD

The FEBS Journal · 2026

DOI: 10.1111/febs.70544 ↗

At a glance

Übersichtsarbeit in The FEBS Journal, 2026. Written by Ebubechukwu Nwarunma and 1 co-authors. Institution: Research Centre for Health, School of Health and Life Sciences, Department of Biological and Biomedical Sciences, Glasgow Caledonian University, UK. Major MEDLINE topics: Multiple Myeloma, Mitochondria, Leukemia, Myeloid, Acute. Cited 1 times so far (Crossref); 61 references. The full text is freely available (open access, CC BY 4.0). Funded by: Tenovus Scotland, The Sylvia Aitken Charitable Trust, The British Society of Haematology.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Haematological malignancies, such as acute myeloid leukaemia (AML) and multiple myeloma (MM), which develop from malignant transformations within the bone marrow, represent the most critical unmet needs in the haemato‐oncology field. Sub‐optimal clinical outcomes in patients with AML and MM are often driven by resistance to chemotherapy. It is well established that cells within the bone marrow microenvironment (BMME) support the proliferation and survival of these blood cancer cells. One of the mechanisms by which these BMME‐resident cells support the malignant cells is through horizontal mitochondrial transfer (HMT), a mechanism well documented as occurring under steady‐state conditions as well as in many cancers. Recent research implicates mitochondrial transfer in BMME‐driven chemoresistance in AML and MM. In this review, we critically analyse current understanding of the role of HMT in supporting the survival and proliferation of AML and MM cells, as well as driving resistance to cytotoxic effects of chemotherapy. We further elucidate various mechanisms, molecular triggers, functional consequences, and therapeutic implications for HMT in AML and MM. Our review also highlights unanswered questions within the HMT field and provides a theoretical basis for further study, giving direction on what is important in translating this knowledge into effective future therapeutic strategies.

Subjects

MeSH terms (MEDLINE)

Multiple MyelomaMitochondriaLeukemia, Myeloid, AcuteHumansTumor MicroenvironmentDrug Resistance, NeoplasmBone MarrowAnimalsCell Proliferation

Author keywords

Horizontal mitochondrial transfer (HMT)Multiple myeloma (MM)acute myeloid leukaemia (AML)bone marrow microenvironment (BMME)chemoresistance

Authors and institutions

  • Research Centre for Health, School of Health and Life Sciences, Department of Biological and Biomedical Sciences, Glasgow Caledonian University, UK.
  • School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, UK.

ORCID profiles: Ebubechukwu Nwarunma, Mark T S Williams

Funding

  • Tenovus Scotland
  • The Sylvia Aitken Charitable Trust
  • The British Society of Haematology
  • The Miss AM Pilkington Charitable Trust
  • The Academy of Medical Sciences
  • Academy of Medical Sciences

Cite

APA

Nwarunma, E., & Williams, M. T. S. (2026). Mitochondrial transfer in acute myeloid leukaemia and multiple myeloma: Mechanisms, consequences and potential therapeutic opportunities. The FEBS Journal. https://doi.org/10.1111/febs.70544

Vancouver

Nwarunma E, Williams MTS. Mitochondrial transfer in acute myeloid leukaemia and multiple myeloma: Mechanisms, consequences and potential therapeutic opportunities. The FEBS Journal. 2026. doi:10.1111/febs.70544

BibTeX
@article{Nwarunma2026,
  author = {Nwarunma, Ebubechukwu and Williams, Mark T S},
  title = {Mitochondrial transfer in acute myeloid leukaemia and multiple myeloma: Mechanisms, consequences and potential therapeutic opportunities},
  journal = {The FEBS Journal},
  year = {2026},
  doi = {10.1111/febs.70544}
}
Start for free →